MedTrace Logo

Mindray Neuromuscular Transmission Transducer

NCT02892045 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2019-06-24

No results posted yet for this study

Summary

A new NMT module from Mindray (Mindray Co. Shenzhen, People's Republic of China.) claims to measure 3 directional accelerography. The aim of the study is to compare the neuromuscular block of rocuronium 0.6 mg/kg (twice the 95% effective dose, ED95) monitored by the NMT versus that monitored by the Relaxometer Mechanomyograph on the other hand in Group 1, and versus the TOF-Watch on the other hand in Group 2 to clinically evaluate the new system for its diagnostic accuracy.

Conditions

  • Neuromuscular Blockade

Interventions

DEVICE

MMG

neuromuscular monitoring device

Sponsors & Collaborators

  • Dalian Medical University

    collaborator OTHER

  • Suez Canal University

    lead OTHER

Principal Investigators

  • Ashraf Dahaba, MD · Suez Canal University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • Bosnia and Herzegovina
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02892045 on ClinicalTrials.gov